The US FDA’s approval of Amtagvi allows its use in patients whose cancer has spread to other parts of the body and cannot be removed with surgery.
Lifileucel, branded as Amtagvi, is a tumor derived immunotherapy composed of a patient’s own disease-fighting white blood cells known as T-cells, with a specific type called tumor-infiltrating lymphocytes . “The potential market for TIL therapy is sizeable, as 90% of all cancers are solid tumors compared to 10% as blood cancers,” Dr Jason Bock, co-founder and CEO of Cell Therapy Manufacturing Center, said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: